Fibrosis Progresses Faster in Patients With Type 2 Diabetes and NAFLD
Researchers examined the time to fibrosis progression among patients with and without type 2 diabetes who had NAFLD.
Researchers examined the time to fibrosis progression among patients with and without type 2 diabetes who had NAFLD.
A report explored associations between weight fluctuations and cardiovascular outcomes in individuals with type 2 diabetes who were treated with canagliflozin.
Researchers evaluated differences in the association between obesity and cardiovascular disease.
Researchers sought to evaluate the effectiveness of social media-based interventions on weight, body mass index, waist circumference, fat, energy intake and physical activity.